ClinicalTrials.Veeva

Menu

Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders

Brown University logo

Brown University

Status and phase

Completed
Phase 2

Conditions

Tobacco Use Disorder

Treatments

Other: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
Other: E-Cigarettes

Study type

Interventional

Funder types

Other
Other U.S. Federal agency
NIH

Identifiers

NCT04090879
CHRMS19-0129
U54DA036114-06 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

While the prevalence of smoking in the United States general population has declined over the past 50 years, there has been little to no decline among people with mental health conditions. Affective Disorders (ADs) are the most common mental health conditions in the US, and over 40% of people with ADs are current smokers. A national policy of reducing the nicotine content of cigarettes has the potential to reduce tobacco use, dependence, and related adverse health outcomes. Controlled trials in psychiatrically-stable smokers have shown that reducing the nicotine content in cigarettes can reduce cigarettes per day (CPD), dependence and tobacco toxicant exposure, with few adverse consequences.

The goal of the proposed trial is to experimentally model whether increasing the availability and appeal of an alternative, non-combusted source of nicotine (e-cigarettes) moderates the effect of altering the nicotine in cigarettes in smokers with ADs. Additionally, investigators will test whether allowing participants to personalize the flavor of the e-liquid alters any moderating effects their availability may have on tobacco cigarette smoking.

Daily smokers with current ADs will be recruited at Brown University and the University of Vermont.

Investigators will study two research cigarettes referred to here as Research Cigarette 1 (RC1) and Research Cigarette 2 (RC2). One of these cigarettes will be a normal nicotine content cigarette and the other will be a reduced nicotine content cigarette. Investigators will study two e-cigarette conditions referred to here as E-Cigarette Condition 1 (EC1) and E-Cigarette Condition 2 (EC2). Both e-cigarette conditions will involve the same commercially available devices and same nicotine-containing e-liquid, but in one condition that e-liquid will be available only in tobacco flavor while in the other condition that e-liquid will be available in multiple flavors from which participants can choose based on personal taste preference. Participants will be assigned to one of the following four study conditions: (1) RC1 only; (2) RC2 only; (3) RC2 + EC1; (4) RC2 + EC2.

Participants will be asked to use only their assigned study products for 16 weeks. Outcome measures include total CPD, cigarette demand assessed by behavioral economics-based purchase tasks, craving, withdrawal, psychiatric symptoms, breath carbon monoxide (CO), biomarkers of tobacco toxicant exposure, brain function and structure, and airway inflammation (fractional nitric oxide concentration in exhaled breath [FeNO]).

Enrollment

326 patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

  • Between 21 years and 70 years old
  • Must have current diagnosis of an Affective Disorder.

Exclusion Criteria

  • Being without an Affective Disorder
  • Younger than 21 years old
  • Older than 70 years old

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

326 participants in 4 patient groups

RC 1 only
Experimental group
Description:
Research Cigarettes #1
Treatment:
Other: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
RC 2 only
Experimental group
Description:
Research Cigarettes #2
Treatment:
Other: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
RC 2 + EC 1
Experimental group
Description:
Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)
Treatment:
Other: E-Cigarettes
Other: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
RC 2 + EC 2
Experimental group
Description:
Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)
Treatment:
Other: E-Cigarettes
Other: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)

Trial documents
2

Trial contacts and locations

2

Loading...

Central trial contact

Shirley Plucinski

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems